Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article

Advertisement

ResearchIn-Press PreviewImmunologyInfectious diseaseMicrobiology Open Access | 10.1172/JCI205523

Targeting virulence factors Psl and PcrV restores host defense in bronchiectasis and cystic fibrosis models

Wanhai Qin,1 Wayne Brailsford,2 Stacey M. Cromer Berman,2 Christina S Thornton,4 Antonio DiGiandomenico,2 and Paul Kubes5

1Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada

2BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

3BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, United States of America

4Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univeristy of Calgary, Calgary, Canada

5Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univerity of Calgary, Calgary, Canada

Find articles by Qin, W. in: PubMed | Google Scholar

1Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada

2BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

3BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, United States of America

4Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univeristy of Calgary, Calgary, Canada

5Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univerity of Calgary, Calgary, Canada

Find articles by Brailsford, W. in: PubMed | Google Scholar

1Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada

2BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

3BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, United States of America

4Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univeristy of Calgary, Calgary, Canada

5Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univerity of Calgary, Calgary, Canada

Find articles by Cromer Berman, S. in: PubMed | Google Scholar

1Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada

2BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

3BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, United States of America

4Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univeristy of Calgary, Calgary, Canada

5Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univerity of Calgary, Calgary, Canada

Find articles by Thornton, C. in: PubMed | Google Scholar

1Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada

2BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

3BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, United States of America

4Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univeristy of Calgary, Calgary, Canada

5Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univerity of Calgary, Calgary, Canada

Find articles by DiGiandomenico, A. in: PubMed | Google Scholar

1Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada

2BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

3BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, United States of America

4Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univeristy of Calgary, Calgary, Canada

5Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, Univerity of Calgary, Calgary, Canada

Find articles by Kubes, P. in: PubMed | Google Scholar

Published September 22, 2026 - More info

J Clin Invest. https://doi.org/10.1172/JCI205523.
Copyright © 2026, Qin et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published September 22, 2026 - Version history
View PDF
Abstract

Chronic Pseudomonas aeruginosa infection is a central driver of bronchiectasis and contributes to progressive lung decline in patients with cystic fibrosis (CF), even in the era of CFTR modulators. A major limitation in the field is that conventional mouse models fail to develop persistent, biofilm-associated lung infection, restricting mechanistic studies and preclinical evaluation. Here, we establish clinically relevant infection models by combining CF-like mouse strains (βENaC-overexpressing and CFTR-deficient mice) with agarose bead–embedded P. aeruginosa that forms persistent, tobramycin-refractory biofilms. Using intravital lung microscopy, we show that alveolar macrophages initially respond by surrounding biofilms but progressively dissociate from the biofilms during persistent infection. Neutrophils are also recruited but fail to clear bacteria. Administration of gremubamab (MEDI3902), a bispecific antibody targeting the virulence factors Psl and PcrV, preserves alveolar macrophages in persistent biofilm infection, restores bacterial sensing and phagocytosis, limits excessive neutrophilic inflammation, and significantly improves bacterial clearance and survival. Together, these findings establish a clinically relevant persistent P. aeruginosa infection model and highlight gremubamab as a promising virulence-targeted therapy to potentially overcome bacterial immune evasion while restoring host defense in mouse models of bronchiectasis and CF.

Supplemental material

View Supplemental vedio 1

View Supplemental vedio 2

View Supplemental vedio 3

View Supplemental vedio 4

View Supplemental vedio 5

View Supplemental vedio 6

View Supplemental vedio 7

View Supplemental vedio 8

View Supplemental vedio 9

View Supplemental vedio 10

View Supplemental vedio 11

View Supplemental vedio 12

View

Version history
  • Version 1 (September 22, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts